Get the Stockscreener App
3.01
31.44%
0.72
After Hours:
3.11
0.10
+3.32%
Acrivon Therapeutics Inc stock is traded at $3.01, with a volume of 3.19M.
It is up +31.44% in the last 24 hours and up +27.00% over the past month.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.
See More
Previous Close:
$2.29
Open:
$2.35
24h Volume:
3.19M
Relative Volume:
4.41
Market Cap:
$94.98M
Revenue:
-
Net Income/Loss:
$-69.00M
P/E Ratio:
-1.0827
EPS:
-2.78
Net Cash Flow:
$-55.26M
1W Performance:
+23.36%
1M Performance:
+27.00%
6M Performance:
+133.33%
1Y Performance:
-55.67%
1-Day Range:
$2.32
$3.15
1-Week Range:
$2.2735
$3.15
52-Week Range:
$1.05
$8.00
Acrivon Therapeutics Inc Stock (ACRV) Company Profile
Name
Acrivon Therapeutics Inc
Sector
Industry
Phone
617-207-8979
Address
480 ARSENAL WAY, SUITE 100, WATERTOWN
Compare ACRV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACRV
Acrivon Therapeutics Inc
|
3.01 | 72.26M | 0 | -69.00M | -55.26M | -2.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Acrivon Therapeutics Inc Stock (ACRV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-05-25 | Resumed | Piper Sandler | Overweight |
| Jan-31-25 | Initiated | KeyBanc Capital Markets | Overweight |
| Sep-16-24 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Apr-29-24 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Mar-01-24 | Initiated | JMP Securities | Mkt Outperform |
| Dec-15-23 | Resumed | Jefferies | Buy |
| Oct-05-23 | Initiated | Maxim Group | Buy |
| Jun-02-23 | Initiated | Oppenheimer | Outperform |
| May-08-23 | Initiated | BMO Capital Markets | Outperform |
| Apr-27-23 | Initiated | Ladenburg Thalmann | Buy |
| Apr-20-23 | Initiated | H.C. Wainwright | Buy |
| Dec-12-22 | Initiated | Cowen | Outperform |
| Dec-12-22 | Initiated | Jefferies | Buy |
| Dec-12-22 | Initiated | Piper Sandler | Overweight |
View All
Acrivon Therapeutics Inc Stock (ACRV) Latest News
Acrivon Therapeutics to announce clinical update on Phase 2b ACR-368 studies - TipRanks
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Acrivon to provide clinical updates on cancer drug candidates By Investing.com - Investing.com South Africa
Acrivon Therapeutics to Release Clinical Data Updates on ACR-368 and ACR-2316 on January 8, 2026 - Quiver Quantitative
Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates via Webcast - The Manila Times
New data on experimental cancer drugs ACR-368 and ACR-2316 coming - Stock Titan
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
Is Acrivon Therapeutics Inc a good long term investmentEarnings Volatility Patterns & Multiply Your Assets With Time-Tested Picks - earlytimes.in
Trend Recap: Why retail investors pile into Acrivon Therapeutics Inc stockWeekly Stock Summary & Weekly Watchlist for Hot Stocks - moha.gov.vn
H.C. Wainwright Initiates Coverage on Acrivon Therapeutics (ACRV) With “Buy” Rating and $19 PT - MSN
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Sahm
Is Acrivon Therapeutics Inc. stock attractive for long term wealth buildingWeekly Trade Analysis & Growth-Oriented Investment Plans - Улправда
Acrivon Therapeutics (NASDAQ:ACRV) Rating Increased to Hold at Wall Street Zen - MarketBeat
What momentum indicators show for Acrivon Therapeutics Inc. stockEarnings Risk Report & Free Weekly Chart Analysis and Trade Guides - Улправда
Will Acrivon Therapeutics Inc. stock attract ESG investors2025 Short Interest & Reliable Trade Execution Plans - Улправда
Is Acrivon Therapeutics Inc. stock a good choice for value investorsQuarterly Profit Report & Safe Capital Allocation Plans - Улправда
Does Acrivon Therapeutics Inc. stock trade at a discount to peersMarket Trend Review & Verified Entry Point Detection - Улправда
What is the fair value of Acrivon Therapeutics Inc. stock nowMarket Activity Summary & Advanced Technical Signal Analysis - DonanımHaber
Why Acrivon Therapeutics Inc. stock could rally in 2025July 2025 Review & Fast Gain Stock Trading Tips - DonanımHaber
How Acrivon Therapeutics Inc. stock compares to market leadersJuly 2025 Volume & Daily Risk Controlled Trade Plans - DonanımHaber
Is Acrivon Therapeutics Inc. stock overvalued by current metricsWeekly Profit Recap & Low Drawdown Trading Techniques - Улправда
Acrivon Therapeutics, Inc.(NasdaqGM: ACRV) dropped from NASDAQ Biotechnology Index - marketscreener.com
Aug Catalysts: Does Acrivon Therapeutics Inc. stock trade at a discount to peersTrade Ideas & Comprehensive Market Scan Reports - ulpravda.ru
Inflation Data: Is Acrivon Therapeutics Inc. stock a good choice for value investorsProduct Launch & High Accuracy Investment Signals - Улправда
CEO Change: What momentum indicators show for Acrivon Therapeutics Inc. stockDividend Hike & High Accuracy Buy Signal Tips - Улправда
Acrivon to provide ACR-368, ACR-2316 clinical data in January - MSN
Acrivon to provide clinical data updates for cancer drugs in January - Investing.com Nigeria
Acrivon Therapeutics to Provide Clinical Data and Updates on ACR-368 and ACR-2316 in January 2026 - Quiver Quantitative
UPDATE -- Acrivon Therapeutics to Announce Clinical Update - GlobeNewswire
UPDATE -- Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates via Webcast - Yahoo Finance
Acrivon Therapeutics to announce clinical update - marketscreener.com
Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates - The Manila Times
Acrivon Therapeutics to Announce Clinical Update on Its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates - 富途牛牛
Acrivon Therapeutics Earnings Notes - Trefis
Acrivon Therapeutics (NASDAQ:ACRV) Downgraded to Sell Rating by Wall Street Zen - MarketBeat
3 Promising Penny Stocks With Market Caps Over $70M - Sahm
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Holdings of Acrivon Therapeutics Inc (ACRV) are aligned with the stars - setenews.com
Volume Report: How Acrivon Therapeutics Inc stock reacts to bond yields2025 Historical Comparison & Growth-Oriented Investment Plans - moha.gov.vn
What drives Acrivon Therapeutics Inc stock priceTrendline Breakouts & Low Cost Capital Growth - earlytimes.in
SBI Cards and Payment Services Limited Stages Intraday Comeback Trend Change - earlytimes.in
How Acrivon Therapeutics Inc. stock reacts to bond yieldsBond Market & AI Forecasted Entry and Exit Points - Newser
ACRV SEC FilingsAcrivon Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Get in on Acrivon Therapeutics Inc’s (ACRV) buy-in window today! - setenews.com
Investors in cash trouble should check out Acrivon Therapeutics Inc (ACRV) - Setenews
Acrivon Therapeutics Inc Stock (ACRV) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):